Background: Topotecan, a topoisomerase I inhibitor that has demonstrated anticancer activity toward leukemias and solid tumors in clinical trials, is eliminated via hepatic and renal routes. However, dosing guidelines for the administration of topotecan to patients with impaired hepatic function have not yet been established. Purpose:
We compared the maximum tolerated doses (MTDs), the toxic effects, and the pharmacokinetics and pharmacodynamics of topotecan in patients who had refractory, malignant, solid tumors and who either had or lacked hepatic injury. The potential role of three substrate markers of liver function (indocyanin green [ICG]-a marker of hepatic blood flow; lorazepam-a substrate marker of hepatic glucuronidation; and antipyrine-a substrate marker for cytochrome P450 activity) in optimizing topotecan doses for patients with liver injury was also evaluated. Methods: Twenty-one cancer patients, 14 of whom had hepatic injury due to metastatic disease, biliary obstruction, or cirrhosis, were treated with intravenously delivered courses of topotecan consisting of 0.5, 1.0, or 1.5 mg/m 2 of drug per day for 5 days. Most patients received more than one course of treatment, with new courses initiated at 3-week intervals. Patient responses (evaluated by tumor measurements) and treatment-induced toxic effects were assessed. Prior to the initiation of topotecan treatment, patients were given intravenous injections of ICG, lorazepam, and antipyrine to determine the plasma pharmacokinetics of these compounds. The pharmacokinetics of topotecan (both the lactone and the carboxylate forms) were determined by analysis of plasma and urine samples collected on the first day of the first course of drug treatment. Scatter plots of area under the plasma concentration versus time curves in relation to percent decreases in either absolute neutrophil count or platelet count were used to explore the pharmacodynamics of topotecan. The Student's t test and the Mann-Whitney U test were used to compare pharmacokinetic parameters between patients with and without abnormal hepatic function. Correlations were assessed using the Spearman's rank correlation coefficient (r,). Reported P values are based on two-tailed tests of significance. Results: Patients with hepatic injury tolerated topotecan doses up to 1.5 mg/m 2 , i.e., the MTD of this drug established in previous studies. The nature and severity of treatment-induced toxic effects and the pharmacokinetics of topotecan were similar in patients with and without liver injury. No differences were observed in the urinary excretion of topotecan between the two patient groups. Clearances of total topotecan and of its lactone species correlated only with clearance of ICG (r s = .64, P = .004; and r, = .68, P = .0017, respectively). The pharmacodynamic effects of topotecan were not altered by liver dysfunction. Conclusions and Implications: Cancer patients with hepatic injury can be treated with topotecan at a starting dose of 1.5 mg/m 2 , given daily for 5 days and administered every 3 weeks. Topotecan dose modifications do not appear to be required for patients with hepatic dysfunction and normal renal function. [J Natl Cancer Instl996;88:817-24]
Topotecan, a synthetic hydrophilic camptothecin analogue that inhibits the release of topoisomerase I from DNA, has demonstrated anticancer activity against leukemias and a variety of solid tumors in phase I clinical trials (/-5); phase II and phase III trials of this agent are currently under way. Topotecan is reversibly hydrolyzed from an active, closed-ring lactone species to a less potent, open-ring carboxylate species in a pH-dependent reaction; at physiologic pH. the equilibrium favors the carboxylate species (6) . A metabolic study (7) of intravenously delivered 14 C-topotecan in rats demonstrated that more than 90% of the administered radioactivity was excreted equally in the stool and urine within 96 hours; most of this excretion occurred during the first 24 hours. In an observation that is consistent with a biliary route of elimination for topotecan, radiolabel was detected in the lumen of the gastrointestinal tract. In a clinical study (6) , approximately 30% of administered topotecan underwent renal excretion within 24 hours. Biliary sampling in one patient revealed maximum topotecan concentrations up to 1.5 times greater than those found in synchronous plasma samples (8) . Other than the closed-and open-ring species, no metabolites of topotecan have been identified; however, some investigators have suggested that demethylation (2) or cytochrome P450-3A-mediated catabolism (9) may occur. To date, neither the hepatic metabolism of topotecan nor its biliary excretion have been evaluated systematically. Furthermore, the effects of abnormal hepatic function on the pharmacology of topotecan are not known. The objectives of this study were I) to examine the effects of liver injury on the disposition of topotecan in patients with refractory, malignant, solid tumors, 2) to determine the principal toxic effects and maximum tolerated dose (MTD) of topotecan in such patients, and 3) to assess the potential role of several substrate markers of liver function (i.e., indocyanin green
[ICG]-a marker of hepatic blood flow; lorazepam-a substrate marker of hepatic glucuronidation; and antipyrine-a substrate marker for cytochrome P450 activity) in optimizing topotecan doses for patients with liver injury.
Patients and Methods

Eligibility
Patients with histologically documented, malignant, solid tumors refractory to conventional therapy or for which no effective therapy currently exists were candidates for this study. Since serum bilirubin level (reflecting the clearance of bilirubin) is related to the sufficiency of hepatic function and not to liver damage per se, patients were assigned on this basis to either a control group (total serum bilirubin level £1.2 mg/dL; seven patients) or a hepatic dysfunction group (serum total bilirubin level >l.2 mg/dL; 14 patients). Eligibility criteria for the study included the following: 1) 18 years of age or older, 2) an Eastern Cooperative Oncology Group performance status of 3 or better, 3) a life expectancy of at least 6 weeks (determined by an experienced oncologist), which would allow the completion of preliminary pharmacologic studies and at least one course of therapy; 4) no major surgery within 14 days or wide-field radiotherapy and/or chemotherapy within 28 days of entering the study protocol (or within at least 6 weeks for those treated with either a nitrosourea or mitomycin); 5) adequate hematopoietic functions (white blood cell [WBC] count >4000/|lL and platelet count >100 000/p;L); 6) no history of hemorrhagic cystitis and fewer than five red blood cells per high-power field on urine microscopy examination; 7) normal renal function (creatinine level <1.3 mg/dL); 8) no biliary stem or nephrostomy tube placement within 7 days of study entry; 9) no deficiency in the enzyme glucose 6-phosphate dehydrogenase; and 10) no concurrent medications that could potentially affect cytochrome P450 enzyme systems, such as amobarbital, carbamazepine, chlorimipramine, cimetidine, tetrahydro-cannabinol, disulfiram, ethanol, ethinyl estradiol/d/-norgesterol, halofenate, L-dopa, methaqualone, diphenhydramine, phenobarbital, quinine, rifampicin, spironolactone, amitriptyline, vitamin C. or allopurinol. All patients gave written, informed consent according to institutional and federal guidelines before treatment.
Drug Doses
The starting dose of topotecan for patients with impaired hepatic function was 0.5 mg/m daily for 5 days, with new courses initiated every 21 days. This dose was one third of the recommended phase II dose (1.5 mg/m" per day) for patients with normal hepatic function. Doses were escalated successively to 1.0 and 1.5 mg/m with cohorts of new patients. At least three untreated patients were entered at each dose level. The MIL) was defined as one dose level below a dose that induced dose-limiting toxic effects, which were defined as one of the following: 1) absolute neutrophil count (ANC) less than 500/jiL or platelet count less than SOOOQ/^L for more than 5 days; 2) ANC less than 500/jiL with fever requiring parenteral antibiotics; and/or 3) nonhematologic toxicity of grade 3 or higher [Common Toxicity Criteria (10)] in one third or more of the patients who had not previously received topotecan. The starting dose of topotecan for control patients was 1.5 mg/m per day. Dose escalations were permitted in a patient if that patient had received at least two courses of treatment at a lower dose level without dose-limiting toxic effects. Dose escalation to 2.0 mg/m" per day was permitted in control patients using identical criteria. Dose reductions, by one dose level, were performed for patients from either group who experienced dose-limiting toxic effects defined by the above MTD criteria.
Drug Administration
Topotecan (SK&F 104864; SmithKline Beecham, King of Prussia, PA) was supplied by the Division of Cancer Treatment, Diagnosis, and Centers (formerly known as the Division of Cancer Treatment), National Cancer Institute (NCI) (Bethesda, MD), in vials containing a lyophilized mixture of 5 mg topotecan and 100 mg mannitol. The pH was adjusted to 3-4 with hydrochloric acid and sodium hydroxide prior to lyophilization. Topotecan was reconstituted in the pharmacy with 2 mL sterile water, and the solubilized drug was diluted with 100 mL 5% dextrose and administered intravenously over 30 minutes. The first two doses of the initial course of treatment were administered at the General Clinical Research Center of The Johns Hopkins Hospital. Subsequent drug administration was performed in the outpatient clinic of The Johns Hopkins Oncology Center.
Pretreatment and Follow-Up Studies
Recording of medical histories, physical examinations, and routine laboratory studies were performed prior to the initiation of treatment and weekly thereafter. The laboratory studies included the following: complete blood cell counts; differential WBC counts; urinalyses; and measurements of electrolytes, prothrombin time, and blood levels of urea nitrogen, creatinine. glucose, total protein, albumin, calcium, phosphate, unc acid, alkaline phosphalase. total and direct bilirubin, alanine aminotransferase, aspartate aminotransferase, and amylase. All patients had an electrocardiogram and a 24-hour urine estimation of creatinine clearance performed prior to study initiation. Creatinine clearance was estimated using the method of Jelliffe (/ /) for five patients with abnormal hepatic function whose 24-hour urine collections were incomplete. Complete blood cell counts were obtained on days 8, 10, and 15 following treatment and every other day if the ANC was 1000/|iL or less. Toxic effects were evaluated according to the NCI Common Toxicity Criteria (10) . For toxicity analysis, patients were considered as heavily pretreated with therapies resulting in long-term hematopoietic dysfunction if they had received either large-field radiation to bone marrow-containing areas, such as the pelvis or the spine, six courses or more of chemotherapy containing an aJkylating agent, or two courses or more of a nitrosourea or mitomycin. Formal tumor measurements were performed after every two courses of treatment, and patients were able to continue therapy if they did not develop progressive disease.
A complete response was defined as the complete disappearance of all active disease in two evaluations separated by a minimum period of 4 weeks; a partial response was defined as a 50% or greater reduction in the sum of the products of the bidimensional diameters of all measurable tumors in two successive measurements made at least 4 weeks apart; and progressive disease was defined as the identification of new lesions or a 25% or greater increase in the sum of the products of the bidimensional diameters of all measurable tumors in two successive measurements made at least 4 weeks apart.
Topotecan Sampling and Assay
The pharmacokinetic behavior of topotecan was assessed on the first day of the first course of treatment. Blood samples were collected in heparinized tubes prior to drug administration, during its infusion (at 5, 10, 15, and 25 minutes), and after its infusion (at 3, 10, 20, and 30 minutes and 1, 2, 3, 4, 8, and 24 hours). Urine was collected continuously in plastic jugs containing 30 mL 6 N HCI in four 6-hour intervals after the first dose of topotecan was administered.
Concentrations of topotecan lactone and total topotecan (total of the lactone plus carboxylate forms) were measured in human plasma; total topotecan was also measured in acidified unne. A reverse-phase, ion-pair high-performance liquid chromatography (HPLC) assay that employed fluorescence detection was used to make these measurements. Blood samples were spun in a centrifuge at lOOOg at room temperature for 10 minutes immediately after they were drawn, and the plasma fraction was recovered. The plasma was deproteimzed by adding 6 mL cold methanol (-20 *C) to each 1 mL of plasma and spinning the mixture in a centrifuge (10 minutes, 500g, 4 *C); the supernatant was recovered and stored at -70 "C. Chromaiographic separation of molecular species was achieved using a 5-um x 4.6-mm x 250-mm ODS-80TM TSK-GEL C, 8 column (TosoHaas, Philadelphia, PA) equipped with a C| 8 Guard-Pak (Waters, Bedford, MA). The mobile phase, which ran at a flow rate of 1 mL/minute. consisted of 25 mj W potassium phosphate buffer/5 rruW 1-heptanesulfonic acid (pH 4.0: 45% vol/vol) and methanol (55% vol/vol). Total topotecan concentrations in plasma were measured after acidification of 500-|iL aliquots of the deproteinized plasma (by addition of 5 pi. 40% phosphoric acid): total topotecan concentrations in urine were measured after appropriate dilution with water (to be in the linear range of the assay). The linear range of lopotecan detection was 5-1000 njW at excitation and emission wavelengths of 382 and 523 nm, respectively. The retention time for lopotecan lactone was 5 minutes, and the limit of detection was 3 nM. The recovery of topotecan from plasma after methanol deproteinization was 97%, 88%, 102%, and 104% at concentrations of 5, 50, 100, and 200 nAf, respectively. The coefficient of variation of intraday reproducibility was 1 \% and 6% at plasma concentrations of 5 and 50 nM, respectively. The coefficient of variation of interday reproducibility, assayed by evaluating slopes from 10 calibration curves generated during a 2-month period, was 109t. Peak areas and final topotecan concentrations in patient specimens were calculated using the P.E. Nelson 2600 chroma-lographic data system (Perkin-Elmer. Mornsville. NC).
Substrate Marker Studies
ICG (Cardio-Green: Hynson. Wescott and Dunning, Baltimore MD) was dissolved in 10 mL supplied diluent to yield a 5-mg/mL solution. Lorazepam (Ativan; Wyeth-Ayerst Laboratories, Philadelphia, PA) was supplied as a 2-mg/mL injectable solution Injectable solutions of antipynne were provided by W. Crom (St. Jude Children's Research Hospital. Memphis, TN) and by L. Thoma (Department of Pharmaceutics, University of Tennessee, Memphis, TN). Antipynne solutions were filtered using 5-um filter needles (B. Braun Medical Inc., Bethlehem, PA) before administration. The three marker compounds were mixed with sterile water to yield a single final solution of 30 mL for injection (12, 13) . Patients were asked to refrain from ingesting food and beverages containing caffeine and chocolate for 3 days prior to administration of the substrate markers.
Seven to 10 days before the start of topotecan therapy, the mixture of lorazepam (0.03 mg/kg), antipyrine (10 mg/kg), and ICG (0.5 mg/kg) was administered intravenously to each patient; these injections were given at the General Clinical Research Center of The Johns Hopkins Hospital, and the infusion period was 5 minutes in duration. For safety reasons, maximum doses of the three markers were set for simultaneous administration to a patient weighing 100 kg. A 10-mL sample of blood was obtained prior to injecting the lorazepam-antipyrine-ICG mixture, and 5-mL samples were collected at 2, 3, 7, 10, 60, and 75 minutes and at 6, 24, and 48 hours after administration. These sampling times were determined by W. Evans and W. Crom (St. Jude Children's Research Hospital) using the DESIGN program (14) , which incorporates the method of Box and Lucas (15) for time point selection. Duplicate samples were obtained at the 60-minule and the 24-and 48-hour sampling times. The blood samples were collected in hepannized vacutainers and subjected to centrifugation (5 minutes, 5420g, room temperature); the plasma was separated and stored at -70 'C.
Lorazepam and antipynne concentrations were assayed by Bioanalytic Systems Inc. (West Lafayette, IN) by modification of a method onginally described by Riley and Evans (16) .
ICG concentrations were also measured by Bioanalytic Systems Inc. (within 2 weeks of sampling). Patient plasma samples were thawed at room temperature, vortex mixed, and clarified by centrifugation. Acetonitrile (100 |iL) was added to each sample prior to the assay. Chromalographic separation was achieved using reverse-phase HPLC on a 3-um x 100-mm x 3.2-mm phase II ODS MF 6213 column (Bioanalytical Systems Inc.). The mobile phase was 590 mL acetate buffer (pH = 4.65; 6.0 g acetic acid and 2 g NaOH per liter of deionized The coefficient of variation of interday reproducibility, assayed by evaluating calculated concentrations of the 0.8-and 8.0-mg/mL calibration standards from 19 calibration curves generated during a 36-month period, were 6.4% and 4.2%, respectively. Calibration curves were analyzed by linear regression.
Pharmacokinetic Analysis
Individual plasma disposition curves for total topotecan, topotecan lactone, lorazepam, and antipynne were best described by a two-compartment linear model using nonlinear least-squares regression analysis (PCNONLIN, Statistical Consultants, Lexington, KY). Individual plasma disposition curves for ICG were best descnbed using either a one-or a two-compartment linear model. Since previous studies of ICG clearance have used shorter plasma sampling times than were used in this study [e.g., see (12) ], the pharmacokinetic analysis of ICG included an assessment of both the apparent clearance based on the initial 20 minutes of sampling and the total drug clearance. All concentration data were weighted by 1/concentration (IT). Disposition half-lives, systemic plasma clearance, area under the plasma concentration versus time curves (AUCs), and the steady state and central volumes of distribution were estimated from the fitted parameters. Pharmacokinetic model discrimination was guided by inspection of the weighted sum of squares, dispersion of the residuals, standard errors of the fitted parameters, and Akaike's information criteria (IS) . In those cases where the data could not be analyzed using nonlinear regression, a mixed linear and logarithmic trapezoidal rule estimate of AUC was obtained (1920); systemic plasma clearance was then derived from the following formula: Systemic plasma clearance = dose administered/plasma AUC. The renal clearance of topotecan was derived by measuring the 24-hour renal excretion of drug and estimating the plasma AUC from time 0-24 hours. This topotecan AUC from time 0-24 hours, derived from the model-estimated parameters, was calculated using a mixed linear and logarithmic trapezoidal rule method (1920).
Data Analysis
The pharmacodynamics of topotecan were explored using scatter plots of AUC versus percentage decrease in ANC, which was defined as: 100 x [(pretreatment ANC -nadir ANC)/pretreaiment ANC]. A similar analysis was performed for the percentage decrease in platelet counts. Relationships were fit with either simple or sigmoidal maximum effect (E^J models (21) using nonlinear least squares regression analysis (PCNONLIN, Statistical Consultants); for ANC, these were defined as: % change in ANC = [(maximum effect AUC) \l [(AUCJQ)* + AUC 1 ]. where k is a parameter that describes the shape or sigmoidicity of the curve and AUCJO is the AUC that results in 50% of the maximum effect (a 100% reduction in ANC). A similar analysis was made for topotecan dose and thrombocytopenia. Comparisons between the pharmacodynamic models were made using the coefficient of determination (r~) and the standard errors for the estimated parameters. Scatterplots were also made of indices of liver dysfunction (e.g., bilirubin level, albumin level, and ICG plasma clearance) and topotecan pharmacokinetic parameters. The Student's I test and nonparametric testing (MannWhitney U test) were used to compare pharmacokinetic parameters between patients with abnormal hepatic function and control patients. Correlations were assessed using the Spearman's rank correlation test (r s ). Logarithmic transformation of the data was performed where appropriate (22) . A P value threshold of .05 was selected as representing statistical significance for parametric and nonparametric tests. All tests for significance were twotailed. An adjustment for multiple comparisons was not performed. Statistical analysis was performed using the Slatistica 5.0 software program (Statsoft, Tulsa, OK).
Results
From October 1992 through April 1994, 21 patients were enrolled in this study. Patient characteristics and the results of hepatic injury tests at the time of registration are shown in Table 1 . Twenty patients were previously treated with chemotherapy; five of seven control patients and three of 14 patients with liver injury had been heavily pretreated. Most of the patients with liver injury had extensive hepatic metastatic disease; two had biliary obstruction, and one had hepatocellular carcinoma secondary to hepatic cirrhosis. Initial serum total bilirubin concentrations in the patients with impaired hepatic function according to the topotecan dose received were as follows: 0.5 mg/m 2 (1.9, 2.1, 2.6, 3.0, 4.0, and 4.9); 1.0 mg/m 2 (1.7, 1.8, 3.3, 3.9, and 14.9); and 1.5 mg/m 2 (3.5, 5.6, and 6.9). The median survival time for these patients was 8 weeks (range, 2-58 weeks).
The median number of courses of topotecan administered to the control patients was five (range, one to 16) (one patient each received one, two, four, five, 10, 12, and 16 courses). The median number of courses administered to patients with abnormal hepatic function was two (range, one to 11) (one course, six patients; two courses, five patients; three courses, one patient; nine courses, one patient; and 11 courses, one patient). Eight of 89 courses of treatment (four first courses) were not fully assessable for toxicity. One patient with hepatic cirrhosis sustained a fractured femur after receiving three doses of topotecan. Following surgery under general anesthesia, hepatic encephalopathy and the hepatorenal syndrome developed. The patient died on day 4 after surgery; an autopsy was not performed. A second patient with liver metastasis from colon cancer also received only three doses of topotecan. Treatment was then discontinued because of disease progression, and hospice care was initiated. A third patient developed progressive hepatic failure due to metastatic colon cancer and died without evidence of hematologic toxicity on day 7 of the first cycle of therapy. Four courses of therapy were interrupted because of one of the following conditions: a central venous catheter infection, gram-negative sepsis, epidural cord compression, or inclement weather. Data collection for one course of therapy was incomplete.
Hematologic Toxicity
Hematologic toxicity, consisting predominantly of neutropenia and anemia, was observed in both groups of patients (Table 2) . Neutropenia was qualitatively similar between the two groups, in that it was well tolerated and promptly resolved. In three patients (one heavily pretreated) with abnormal hepatic function who received 12 courses of topotecan at 1.5 mg/m 2 , no episodes of neutropenic fever or grade 4 neutropenia were observed. However, in six assessable patients (five heavily pretreated) with normal liver function who were treated at the same dose level, grade 4 neutropenia was observed in 23 of 46 courses. No episodes of neutropenic fever or sepsis occurred during the study, and treatment delays due to neutropenia were not observed.
Two patients with impaired hepatic function received multiple cycles of therapy. One of these patients with fluorouracilrefractory colon cancer and obstructive jaundice had a minor response to therapy and normalization of serum bilirubin levels; a trend toward reduced neutropenia was observed with successive cycles of treatment. The second patient had fluctuating hyperbilirubinemia that did not correlate with the ANC nadir of each course of treatment. Anemia and thrombocytopenia were both mild in severity and qualitatively similar in both groups of patients (Table 2) . •"New" refers to number of patients initially entered at a given dose level; "assessable" refers to the total number of assessable patients at that dose level, i Absolute neutrophil count. $Mean value ± standard deviation.
Nonhematologic Toxicity
Diarrhea, fatigue, mucositis, nausea, and vomiting were the predominant nonhematologic toxic effects observed in both patient groups. The nature and severity of these toxic effects were similar in both cohorts of patients. Symptoms were usually of mild-to-moderate severity and were attenuated with supportive care. Alopecia, of grade 1 severity when evaluable, was observed in both groups.
Pharmacokinetics of Topotecan
Pharmacokinetic studies of topotecan were performed in 20 patients (seven control subjects and 13 patients with hepatic dysfunction). Plasma disposition curves of total topotecan were best described by a two-compartment model for 18 patients. For the remaining two patients, nonlinear regression analysis could not be performed due to unacceptably large standard errors (>25%) for the kinetic parameter values, and a trapezoidal rule estimate of AUC was obtained. Plasma disposition curves of topotecan lactone were best described using one-compartment (five patients) or two-compartment (15 patients) models. Urinary drug excretion was measured in five control subjects and 12 patients with hepatic dysfunction.
No statistically significant differences were observed between the pharmacokinetic indices of either total topotecan or topotecan lactone species between treatment groups (Table 3 ). In the two patients who died within 1 week of treatment, similar plasma clearances of topotecan and its lactone species were observed compared with other patients. The median ratios of topotecan lactone AUC to topotecan total AUC were 0.26 (range, 0.1-0.82) and 0.34 (range, 0.17-0.48) for patients with and without hepatic injury, respectively. Estimates of both the 24-hour urinary excretion of topotecan ± standard deviation (SD) (21.3% ± 14.4% versus 19.5% ± 8.6%) and the renal clearance of topotecan ± SD (130 ± 84 versus 150 ± 110 mL/minutes) were similar between patients with and without liver injury, respectively (Table 3 ). In patients with hepatic dysfunction, a twofold to fourfold range of total topotecan AUC and a fivefold to 10-fold range of topotecan lactone AUC was observed at each dose level. 
Pharmacokinetics of Lorazepam, Antipyrine, and ICG
Substrate markers were administered, and pharmacokinetic data were complete for antipyrine, lorazepam, and ICG in 20, 19, and 18 patients, respectively. Plasma disposition curves were best described using one-or two-compartment models. A trend toward reduced plasma clearance of both antipyrine and ICG was observed in patients with liver injury (Table 3) . The mean plasma clearance of lorazepam was higher in these patients due to the presence of outlier values.
Linear correlations were observed between ICG clearance and the clearances of total topotecan (r, = .64; P = .004) and topotecan lactone (r s = .68; P -.002). Statistically significant correlations were not observed when the initial 20-minute clearance of ICG was assessed. Similarly, the clearances of antipyrine and lorazepam did not correlate with those of either total topotecan or topotecan lactone. Other than correlations between the clearance of topotecan lactone and the clearances of log lactate dehydrogenase level (r s = -.62; P = .005) and log albumin level (r, = .48; P -.02), no statistically significant correlations were observed between base-line liver chemistry parameters and the clearances of either total topotecan or topotecan lactone.
Pharmacodynamics
Scatterplots of total topotecan AUC versus the percentage change in either ANC or platelet counts for all of the patients are shown in Fig. 1, A and B , respectively. The estimated ED50S (i.e., doses associated with 50% reductions in count) ± standard errors of the mean were an AUC of 4940 ±414 nMminute (r 2 = .72) for neutrophils and 6650 ± 53.6 nMminute (i 2 -.54) for platelets. Linear models were predictive of these relationships as would be expected, but they fit the data poorly. Relationships between the degree of myelosuppression and either topotecan lactone AUC or total topotecan AUC in patients with liver injury could not be described using either linear or Em,, models. Scatterplots of the percent change in either ANC or platelet counts and the indices of liver function used in this study did not reveal any correlations.
The effects of topotecan dose on the percent changes in neutrophil or platelet counts for patients with hepatic dysfunction are also shown in Fig. 1 
Discussion
Patients with impaired hepatic function tolerate topotecan doses of 1.5 mg/m 2 administered daily for 5 days, i.e., the maximum tolerated dose defined in previously reported studies of this drug (/ J.4.6) . In fact, dose escalation to 1.5 mg/m 2 per day was tolerated without evidence of doselimiting toxicity in patients with hepatic injury. Since this dose was the one previously established in phase II clinical trials, further patient accrual was halted. The absence of grade 4 neutropenia in three patients with liver injury who received a total of 12 courses of topotecan at 1.5 mg/m 2 per day for 5 days was unexpected, but may be due to chance alone. Alternatively, the lack of significant hematologic toxicity may reflect the minimal prior therapy received by this cohort of patients when compared with patients in the control group. Ultimately, if a larger number of patients with liver injury demonstrate less neutropenia than control patients, the possibility of an active metabolite contributing to topotecan's cytotoxicity could be raised. An alternative explanation is that enterohepatic recirculation of topotecan may have been reduced in these patients. No differences were evident in the distribution or clearance of either total topotecan or topotecan lactone between patients with and without impaired hepatic function. Furthermore, these values and the intrapatient variability in AUC were not significantly different from those reported in other phase I trials of topotecan in which a similar dosing schedule was used (7, 5) . Pharmacodynamic analysis demonstrated that the estimated ED^ in patients with hepatic injury is 1.0 mg/m 2 per day. This finding is consistent with those of phase 1 trials in patients with normal liver function in which ED 5O s of 0.6-0.8 mg/m 2 per day were reported (4, 6) .
A preclinical study (7) of '^-topotecan excretion in rats indicated that hepatic and renal excretion are equally important routes of topotecan elimination. The lack of correlation between the clearance of topotecan and the clearance of either antipyrine or lorazepam indicates that none of the specific cytochrome P450s [CYP1A2, CYP2C, and CYP3A (23)] and glucuronyl transferase enzymes used by these substrate markers represents a major route of topotecan metabolism. However, since lorazepam binds extensively to plasma proteins, its clearance is sensitive to alterations in albumin levels. In those patients with impaired hepatic function, reduced levels of serum albumin may have confounded an assessment of the role of glucuronyl transferase enzymes in the metabolism of topotecan. In addition, since both glucuronyl transferases and cytochrome P450s are members of complex families of enzymes (24, 25) , the clearances of lorazepam and antipyrine reflect the activities of only certain specific isoenzymes. Hence, a lack of correlation does not exclude a role for these enzyme systems in topotecan metabolism. Linear correlations were observed between ICG and topotecan clearances. Although liver blood flow has traditionally been regarded as the major determinant of ICG clearance (26) , a more recent study (27) has demonstrated that the hepatic extraction ratio of ICG varies from 0.5 to 0.8 and declines in patients with parenchymal liver disease.
Therefore, other factors may be important determinants of ICG clearance (23) and may not reflect the underlying mechanism of topotecan elimination.
In vitro studies of protein binding of camptothecin and its analogues demonstrate that the differential binding of the lactone and carboxylate forms of these drugs to albumin may have important pharmacodynamic implications. Albumin binds with high affinity to the carboxylate form of camptothecin, and, therefore, camptothecin is rapidly converted to its inactive carboxylate form after administration (28) . However, neither species of topotecan interacts strongly with albumin (29) . A clonogenic assay study (30) has demonstrated that the addition of albumin to MCF-7 cells significantly reduces the cytotoxicity of camptothecin but not of topotecan. These in vitro observations are consistent with the demonstration that, despite significant differences in serum albumin levels, similar pharmacologic effects of topotecan were observed in both groups of patients, and they provide further evidence that the binding of topotecan to plasma proteins is not important pharmacologically.
Studies (31, 32) of etoposide disposition in patients with impaired hepatic function have demonstrated that a modest increase in renal drug clearance compensates for reduced hepatic metabolism of the drug. In our study, such a compensatory increase was not observed. One possible explanation is that hepatic processes involved in the elimination of topotecan may be better preserved compared with those involved in etoposide excretion.
We conclude that, in patients with hepatic injury (defined in this study by a serum total bilirubin level of greater than 1.2 mg/dL), dose adjustments of topotecan administered on a daily x 5-day schedule are not required. No pharmacokinetic or pharmacodynamic alterations were found in individuals with impaired hepatic function when compared with a control group of patients and patients enrolled in other phase I studies (13, 4, 6 ) of this drug. The lack of correlation between any of the clinical indices of liver function (e.g., albumin level and lactate dehydrogenase level) and the pharmacokinetic parameters of topotecan is also consistent with these results. The mechanism by which drug clearance remains unaltered in patients with liver dysfunction is unclear. Increased urinary excretion of topotecan does not appear to be responsible.
